Phage Therapy: Towards a Successful Clinical Trial
- PMID: 33227949
- PMCID: PMC7699228
- DOI: 10.3390/antibiotics9110827
Phage Therapy: Towards a Successful Clinical Trial
Abstract
While phage therapy carried out as compassionate use (experimental therapy) has recently flourished, providing numerous case reports of supposedly healed patients, clinical trials aiming to formally prove their value in accord with current regulatory requirements have failed. In light of the current issue of increasing antibiotic resistance, the need for a final say regarding the place of phage therapy in modern medicine is evident. We analyze the possible factors that may favor success or lead to the failure of phage therapy: quality of phage preparations, their titer and dosage, as well as external factors that could also contribute to the outcome of phage therapy. Hopefully, better control of these factors may eventually bring about long-awaited positive results.
Keywords: antibiotic resistance; clinical trial; phage therapy.
Conflict of interest statement
A. Górski, R. Międzybrodzki and J. Borysowski are co-inventors of patents owned by the Hirszfeld Institute of Immunology and Experimental Therapy.
References
-
- Leitner L., Ujmajuridze A., Chanishvili N., Goderdzishvili M., Chkonia I., Rigvava S., Chkhotua A., Changashvili G., McCallin S., Schneider M.P., et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: A randomised, placebo-controlled, double-blind clinical trial. Lancet Infect. Dis. 2020:1473. doi: 10.1016/S1473-3099(20)30330-3. - DOI - PubMed
-
- Alam Sarker S., Sultana S., Reuteler G., Moine D., Descombes P., Charton F., Bourdin G., McCallin S., Ngom-Bru C., Neville T., et al. Oral Phage Therapy of Acute Bacterial Diarrhea With Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh. EBioMedicine. 2016;4:124–137. doi: 10.1016/j.ebiom.2015.12.023. - DOI - PMC - PubMed
-
- Jault P., Leclerc T., Jennes S., Pirnay J.-P., Que Y.-A., Resch G., Rousseau A.F., Ravat F., Carsin H., Le Floch R., et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): A randomised, controlled, double-blind phase 1/2 trial. Lancet Infect. Dis. 2019;19:35–45. doi: 10.1016/S1473-3099(18)30482-1. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
